EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation

Esben Herborg Henriksen iD, Rikke Mulvad Sandvik iD, Mette Frahm Olsen, Tacjana Pressler, Thomas Bryrup iD, Christian Leo-Hansen, Bibi Uhre Nielsen, Christine Højte, Marianne Skov, Frederik Buchvald, Inger Hee Mabuza Mathiesen, Tavs Qvist und 6 weitere

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Esben Herborg Henriksen und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Danish Cystic Fibrosis Cohort, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The study was funded by Vertex Pharmaceuticals..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Elexacaftor/tezacaftor/ivacaftor (ETI) is a breakthrough therapy for cystic fibrosis (CF). We aimed to assess ETI's real‐world impact on peripheral airway disease assessed as ventilation distribution inhomogeneity using nitrogen multiple breath washout (N 2 MBW) in children aged 6–17 years. Additionally, we compared the two outcomes, lung clearance index (LCI), and ventilation distribution efficiency (VDE), as VDE is considered to adjust for a theoretical overestimation of lung disease when using LCI.

Methods

This nationwide study included data from N 2 MBW performed during routine clinical care. Linear mixed effect regression was used to assess changes in LCI and VDE after 12 months of ETI treatment. Subgroup analyses included baseline age (6–11 vs. 12–1 years) and disease severity (normal‐moderate vs. severe‐very severe).

Results

We included 131 children (78% homozygous for F508del mutation, mean [SD] age 11.5 [3.4]), and 339 N 2 MBW tests. The median (range) number of tests per child was 3 (1‐10). The estimated mean (95% CI) 12‐months post‐ETI improvement in LCI and VDE were 1.7 units (−2.1; −1.2, p < 0.001) and 2.1%‐point (1.6; 2.6, p < 0.001), respectively. Similar LCI and VDE improvements were observed across age groups. Using VDE, fewer children were categorized with very severe lung disease, and the ETI‐effect did not differ between the severity groups, unlike LCI.

Conclusion

Our research demonstrates that ETI treatment significantly improves lung function, as measured by N 2 MBW, in Danish children and adolescents with CF. VDE improvements were consistent across age and disease severity groups. In contrast, LCI revealed larger effect estimates for those with severe to very‐severe lung impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesQuinolonesIndolesPyrazolesPyridinesLungPyrrolidinesHumansChildAdolescentMaleFemaleDrug CombinationsTreatment OutcomeRespiratory Function TestsSeverity of Illness IndexChloride Channel AgonistsQuinolines

Stichwörter der Autor:innen

LCIVDEcystic fibrosiselexacaftor/tezacaftor/ivacaftorreal world study

Substanzen

AminophenolsBenzodioxolesDrug CombinationsQuinolonesIndolesPyrazolesPyridinesPyrrolidinesChloride Channel Agonistselexacaftor, ivacaftor, tezacaftor drug combination

Autor:innen und Institutionen

  • The Danish Cystic Fibrosis Cohort, Copenhagen, Denmark.
  • Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
  • Department of Pediatrics and Adolescents Medicine, Danish Center of Pediatric Pulmonology and Allergology, University Hospital of Aarhus, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

ORCID-Profile: Esben Herborg Henriksen, Rikke Mulvad Sandvik, Thomas Bryrup, Sune Rubak, Camilla Bjørn Jensen

Förderung

  • The study was funded by Vertex Pharmaceuticals.

Zitieren

APA

Henriksen, E. H., Sandvik, R. M., Olsen, M. F., Pressler, T., Bryrup, T., Leo-Hansen, C., Nielsen, B. U., Højte, C., Skov, M., Buchvald, F., Mathiesen, I. H. M., Qvist, T., Olesen, H. V., Rubak, S., Jensen, C. B., Faurholt-Jepsen, D., Nielsen, K. G., & TransformCF Study Group (2025). Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71166

Vancouver

Henriksen EH, Sandvik RM, Olsen MF, Pressler T, Bryrup T, Leo-Hansen C, et al. Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71166

BibTeX
@article{Henriksen2025,
  author = {Henriksen, Esben Herborg and Sandvik, Rikke Mulvad and Olsen, Mette Frahm and Pressler, Tacjana and Bryrup, Thomas and Leo-Hansen, Christian and Nielsen, Bibi Uhre and Højte, Christine and Skov, Marianne and Buchvald, Frederik and Mathiesen, Inger Hee Mabuza and Qvist, Tavs and Olesen, Hanne Vebert and Rubak, Sune and Jensen, Camilla Bjørn and Faurholt-Jepsen, Daniel and Nielsen, Kim Gjerum and TransformCF Study Group, TransformCF Study Group},
  title = {Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71166}
}
Kostenlos starten →